Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis
出版年份 2021 全文链接
标题
Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis
作者
关键词
-
出版物
Scientific Reports
Volume 11, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-07-28
DOI
10.1038/s41598-021-94945-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease
- (2021) Zien Zhou et al. STROKE
- Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial
- (2020) Thomas A. Zelniker et al. CIRCULATION
- Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
- (2020) Olivia R Ghosh-Swaby et al. Lancet Diabetes & Endocrinology
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis
- (2019) Fotios Barkas et al. EUROPEAN JOURNAL OF NEUROLOGY
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects
- (2019) Motoaki Sano et al. CIRCULATION
- Subtype‐Dependent Reporting of Stroke With SGLT2 Inhibitors: Implications From a Japanese Pharmacovigilance Study
- (2019) Kenichiro Sato et al. JOURNAL OF CLINICAL PHARMACOLOGY
- SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta-analysis
- (2018) Man Guo et al. DIABETES OBESITY & METABOLISM
- Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
- (2018) Elisabetta Patorno et al. BMJ-British Medical Journal
- Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
- (2018) Elisabetta Patorno et al. BMJ-British Medical Journal
- Imaging the Effects of β-Hydroxybutyrate on Peri-Infarct Neurovascular Function and Metabolism
- (2018) Paolo Bazzigaluppi et al. STROKE
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Stroke in Type 2 Diabetes Mellitus
- (2018) Zien Zhou et al. STROKE
- Hemoglobin concentration and the risk of hemorrhagic and ischemic stroke in patients undergoing hemodialysis: the Q-cohort study
- (2017) Ryusuke Yotsueda et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
- (2017) Bernard Zinman et al. STROKE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet
- (2016) Ji Hye Han et al. DIABETOLOGIA
- Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
- (2016) Xinfang Xie et al. LANCET
- Pioglitazone for Secondary Stroke Prevention
- (2016) Meng Lee et al. STROKE
- Hematocrit and the risk of cardiovascular disease in a Japanese community: The Hisayama Study
- (2015) Seiji Gotoh et al. ATHEROSCLEROSIS
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
- (2015) Silvio E Inzucchi et al. Diabetes & Vascular Disease Research
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
- (2014) William L. Baker et al. Journal of the American Society of Hypertension
- The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
- (2014) Matthias Oelze et al. PLoS One
- SGLT2 inhibition — a novel strategy for diabetes treatment
- (2010) Edward C. Chao et al. NATURE REVIEWS DRUG DISCOVERY
- Classification of Stroke Subtypes
- (2009) P. Amarenco et al. CEREBROVASCULAR DISEASES
- Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials
- (2009) Kausik K Ray et al. LANCET
- Glucose neurotoxicity
- (2007) David R. Tomlinson et al. NATURE REVIEWS NEUROSCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now